About: Martin Bortlík

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Martin Bortlík Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher ORCID ID = 0000-0002-6769-3003

Attributes	Values
rdf:type	Item
description	forskare (sv) 연구원 (ko) 研究者 (ja) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn) изилдөөчү (ky) 研究者 (zh) gastroenterolog (cs) researcher ORCID ID = 0000-0002-6769-3003 (en)
rdfs:label	Martin Bortlík (cs) Martin Bortlík (de) Martin Bortlík (en) Martin Bortlík (es) Martin Bortlík (nl) Martin Bortlík (sk) Martin Bortlík (ast)
skos:prefLabel	Martin Bortlík (cs) Martin Bortlík (de) Martin Bortlík (en) Martin Bortlík (es) Martin Bortlík (nl) Martin Bortlík (sk) Martin Bortlík (ast)
name	Martin Bortlík (cs) Martin Bortlík (de) Martin Bortlík (en) Martin Bortlík (es) Martin Bortlík (nl) Martin Bortlík (sk) Martin Bortlík (ast)
Scopus author ID	wds:Q58883390-27B609E8-C04B-4F73-9EAE-F063A2256CD7
Scopus author ID	6603639541
given name	wds:Q58883390-B2C876E8-59DF-4654-8A68-6B6286472774
given name	Martin
described by source	wds:Q58883390-699315A0-0917-4272-B2B3-8250092F280D
instance of	wds:Q58883390-7A65C67D-7DE2-4FB3-9E27-63B3CEDB08A5
NL CR AUT ID	wds:Q58883390-537b96dc-419a-c054-deb1-29d919c80a1f
described by source	Medvik
instance of	Homo sapiens
NL CR AUT ID	xx0058264
vedidk ID	wds:Q58883390-73FEE4FF-38E8-405B-9F3A-1A6E48933283
vedidk ID	3265331
occupation	wds:Q58883390-7ED84B65-F590-4028-9AA3-9A43D978B47B wds:Q58883390-C3E4F4A1-8D4E-4BEB-AE4A-63093262D472
employer	wds:Q58883390-7646215A-CA87-4020-AB9A-7D6463C84B5A
place of birth	wds:Q58883390-287FEABD-04DD-4A4A-81FA-CB386F914CB2
sex or gender	wds:Q58883390-21178A02-35F4-4BDA-A3BD-C716B3543184
VIAF ID	wds:Q58883390-719CCE1A-6F7F-40F4-8017-7180784206D6
date of birth	wds:Q58883390-AF42506C-9972-4C7E-9070-E31BEE65CC4C
family name	wds:Q58883390-46046510-A644-4F46-8FD2-4A8FBA50DFB8
WorldCat Identities ID (superseded)	wds:Q58883390-FEE36AB3-075B-4423-8447-A5FDE2D6B80B
VIAF ID	http://viaf.org/viaf/85676904
occupation	researcher gastroenterologist
employer	First Faculty of Medicine, Charles University
place of birth	Litoměřice
sex or gender	male
VIAF ID	85676904
date of birth	1970-01-01 00:00:00Z (xsd:dateTime)
family name	Bortlík
WorldCat Identities ID (superseded)	viaf-85676904
ORCID iD	wds:Q58883390-405B3CC5-12EF-4560-AEB5-92C555056CFF
ORCID iD	https://orcid.org/0000-0002-6769-3003
ORCID iD	0000-0002-6769-3003
ResearcherID	wds:Q58883390-54D3E900-8B11-4FCA-BE53-36B1C63DCC3F
ResearcherID	G-2769-2017
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58883390
is author of	Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study. DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic Mutation analysis of the MYH gene in unrelated Czech APC mutation-negative polyposis patients. Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence Infliximab dependency is related to decreased surgical rates in adult Crohnʼs disease patients Non-adherence to treatment in inflammatory bowel disease in Czech Republic Polymorphisms of the TPMT gene in the Czech healthy population and patients with inflammatory bowel disease. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. Nonadherence in inflammatory bowel disease: results of factor analysis [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests] Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study. Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre. Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis. Fatal myelotoxicity after azathioprine treatment. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: Calprotectin and IL-6 changes do not correspond to sRAGE changes [Choice of surgical procedure in operations for chronic pancreatitis--personal experience] [Risk of drug interactions and their possible solutions in the population of patients with inflammatory bowel disease]

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software